451 related articles for article (PubMed ID: 29146881)
1. β-Adrenergic Signaling Impairs Antitumor CD8
Nissen MD; Sloan EK; Mattarollo SR
Cancer Immunol Res; 2018 Jan; 6(1):98-109. PubMed ID: 29146881
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral CD8
Horton BL; Williams JB; Cabanov A; Spranger S; Gajewski TF
Cancer Immunol Res; 2018 Jan; 6(1):14-24. PubMed ID: 29097422
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Efficacy of 4-1BB Costimulation Is Abrogated by PD-1 Blockade in a Model of Spontaneous B-cell Lymphoma.
McKee SJ; Doff BL; Soon MS; Mattarollo SR
Cancer Immunol Res; 2017 Mar; 5(3):191-197. PubMed ID: 28115358
[TBL] [Abstract][Full Text] [Related]
4. CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
Ren Z; Guo J; Liao J; Luan Y; Liu Z; Sun Z; Liu X; Liang Y; Peng H; Fu YX
Clin Cancer Res; 2017 Jan; 23(1):193-203. PubMed ID: 27354469
[TBL] [Abstract][Full Text] [Related]
5. PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8
Buchan SL; Fallatah M; Thirdborough SM; Taraban VY; Rogel A; Thomas LJ; Penfold CA; He LZ; Curran MA; Keler T; Al-Shamkhani A
Clin Cancer Res; 2018 May; 24(10):2383-2394. PubMed ID: 29514845
[No Abstract] [Full Text] [Related]
6. Blockade of β-Adrenergic Receptors Improves CD8
Daher C; Vimeux L; Stoeva R; Peranzoni E; Bismuth G; Wieduwild E; Lucas B; Donnadieu E; Bercovici N; Trautmann A; Feuillet V
Cancer Immunol Res; 2019 Nov; 7(11):1849-1863. PubMed ID: 31527069
[TBL] [Abstract][Full Text] [Related]
7. The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8
Frey AB
Cancer Immunol Res; 2017 Oct; 5(10):920-928. PubMed ID: 28874354
[TBL] [Abstract][Full Text] [Related]
8. Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy.
Hosoi A; Takeda K; Nagaoka K; Iino T; Matsushita H; Ueha S; Aoki S; Matsushima K; Kubo M; Morikawa T; Kitaura K; Suzuki R; Kakimi K
Sci Rep; 2018 Jan; 8(1):1058. PubMed ID: 29348598
[TBL] [Abstract][Full Text] [Related]
9. NKT Cell-Driven Enhancement of Antitumor Immunity Induced by Clec9a-Targeted Tailorable Nanoemulsion.
Lam PY; Kobayashi T; Soon M; Zeng B; Dolcetti R; Leggatt G; Thomas R; Mattarollo SR
Cancer Immunol Res; 2019 Jun; 7(6):952-962. PubMed ID: 31053598
[TBL] [Abstract][Full Text] [Related]
10. The Antitumor Effects of Vaccine-Activated CD8
Wu S; Zhu W; Peng Y; Wang L; Hong Y; Huang L; Dong D; Xie J; Merchen T; Kruse E; Guo ZS; Bartlett D; Fu N; He Y
Cancer Immunol Res; 2017 Oct; 5(10):908-919. PubMed ID: 28851693
[TBL] [Abstract][Full Text] [Related]
11. B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.
Zhao X; Zhang Z; Moreira D; Su YL; Won H; Adamus T; Dong Z; Liang Y; Yin HH; Swiderski P; Pillai RK; Kwak L; Forman S; Kortylewski M
Mol Ther; 2018 Mar; 26(3):695-707. PubMed ID: 29433938
[TBL] [Abstract][Full Text] [Related]
12. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
[TBL] [Abstract][Full Text] [Related]
13. Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.
Sanders KL; Fox BA; Bzik DJ
Cancer Immunol Res; 2015 Aug; 3(8):891-901. PubMed ID: 25804437
[TBL] [Abstract][Full Text] [Related]
14. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.
Manches O; Plumas J; Lui G; Chaperot L; Molens JP; Sotto JJ; Bensa JC; Galili U
Haematologica; 2005 May; 90(5):625-34. PubMed ID: 15921377
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
16. SLAMF6 as a Regulator of Exhausted CD8
Yigit B; Wang N; Ten Hacken E; Chen SS; Bhan AK; Suarez-Fueyo A; Katsuyama E; Tsokos GC; Chiorazzi N; Wu CJ; Burger JA; Herzog RW; Engel P; Terhorst C
Cancer Immunol Res; 2019 Sep; 7(9):1485-1496. PubMed ID: 31315913
[TBL] [Abstract][Full Text] [Related]
17. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
18. Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects.
Joseph AM; Srivastava R; Zabaleta J; Davila E
Cancer Immunol Res; 2016 Aug; 4(8):708-16. PubMed ID: 27267778
[TBL] [Abstract][Full Text] [Related]
19. CD8(+)NKT-like cells regulate the immune response by killing antigen-bearing DCs.
Wang C; Liu X; Li Z; Chai Y; Jiang Y; Wang Q; Ji Y; Zhu Z; Wan Y; Yuan Z; Chang Z; Zhang M
Sci Rep; 2015 Sep; 5():14124. PubMed ID: 26369936
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-7 Modulates Anti-Tumor CD8+ T Cell Responses via Its Action on Host Cells.
Deiser K; Stoycheva D; Bank U; Blankenstein T; Schüler T
PLoS One; 2016; 11(7):e0159690. PubMed ID: 27447484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
